Korean J Radiol.  2015 Dec;16(6):1341-1348. 10.3348/kjr.2015.16.6.1341.

Prediction of Response to Concurrent Chemoradiotherapy with Temozolomide in Glioblastoma: Application of Immediate Post-Operative Dynamic Susceptibility Contrast and Diffusion-Weighted MR Imaging

Affiliations
  • 1Department of Radiology, Seoul National University College of Medicine, Seoul 03080, Korea. verocay@snuh.org
  • 2Center for Nanoparticle Research, Institute for Basic Science, and School of Chemical and Biological Engineering, Seoul National University, Seoul 08826, Korea.
  • 3Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, Korea.
  • 4Department of Neurosurgery, Seoul National University College of Medicine, Seoul 03080, Korea.
  • 5Department of Pathology, Seoul National University College of Medicine, Seoul 03080, Korea.
  • 6Department of Radiation Oncology, Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, Korea.

Abstract


OBJECTIVE
To determine whether histogram values of the normalized apparent diffusion coefficient (nADC) and normalized cerebral blood volume (nCBV) maps obtained in contrast-enhancing lesions detected on immediate post-operative MR imaging can be used to predict the patient response to concurrent chemoradiotherapy (CCRT) with temozolomide (TMZ).
MATERIALS AND METHODS
Twenty-four patients with GBM who had shown measurable contrast enhancement on immediate post-operative MR imaging and had subsequently undergone CCRT with TMZ were retrospectively analyzed. The corresponding histogram parameters of nCBV and nADC maps for measurable contrast-enhancing lesions were calculated. Patient groups with progression (n = 11) and non-progression (n = 13) at one year after the operation were identified, and the histogram parameters were compared between the two groups. Receiver operating characteristic (ROC) analysis was used to determine the best cutoff value for predicting progression. Progression-free survival (PFS) was determined with the Kaplan-Meier method and the log-rank test.
RESULTS
The 99th percentile of the cumulative nCBV histogram (nCBV C99) on immediate post-operative MR imaging was a significant predictor of one-year progression (p = 0.033). ROC analysis showed that the best cutoff value for predicting progression after CCRT was 5.537 (sensitivity and specificity were 72.7% and 76.9%, respectively). The patients with an nCBV C99 of < 5.537 had a significantly longer PFS than those with an nCBV C99 of ≥ 5.537 (p = 0.026).
CONCLUSION
The nCBV C99 from the cumulative histogram analysis of the nCBV from immediate post-operative MR imaging may be feasible for predicting glioblastoma response to CCRT with TMZ.

Keyword

Glioblastoma; Temozolomide; Apparent diffusion coefficient; Cerebral blood volume; Histogram analysis

MeSH Terms

Adult
Aged
Antineoplastic Agents, Alkylating/*therapeutic use
Brain/pathology/radiography
Brain Neoplasms/*drug therapy/mortality/radiography
Chemoradiotherapy
Dacarbazine/*analogs & derivatives/therapeutic use
Diffusion Magnetic Resonance Imaging
Disease Progression
Disease-Free Survival
Female
Glioblastoma/*drug therapy/mortality/radiography
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Proportional Hazards Models
ROC Curve
Retrospective Studies
Antineoplastic Agents, Alkylating
Dacarbazine
Full Text Links
  • KJR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error